Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-03-31 | MYOS | Myos Rens Technology Inc. | Mannello Joseph | CEO, 10% | P - Purchase | $0.00 | +16,529 | 1,387,557 | +1% | +$0 | ||||||
2020-03-31 | MYOS | Myos Rens Technology Inc. | Dewey Christopher C | Dir | P - Purchase | $0.00 | +6,611 | 328,982 | +2% | +$0 | ||||||
2020-03-31 | MYOS | Myos Rens Technology Inc. | Ponte Andrew Joel | Dir | P - Purchase | $0.00 | +3,306 | 97,499 | +4% | +$0 | ||||||
| M | 2020-04-02 | TFFP | Tff Pharmaceuticals, Inc. | Fletcher Aaron G.L. | Dir | P - Purchase | $4.04 | +23,500 | 69,419 | +51% | +$94,873 | |||||
| M | 2020-03-27 | NLTX | Neoleukin Therapeutics, Inc. | Redmile Group, LLC | 10% | P - Purchase | $10.35 | +194,300 | 4,041,211 | +5% | +$2,011,281 | |||||
| M | 2020-04-01 | NLTX | Neoleukin Therapeutics, Inc. | Redmile Group, LLC | 10% | S - Sale | $11.19 | -19,668 | 4,041,211 | 0% | -$220,155 | |||||
| M | 2020-04-02 | SPPI | Spectrum Pharmaceuticals Inc | Lebel Francois | Chief Medical Officer | S - Sale | $2.18 | -2,082 | 309,596 | -1% | -$4,529 | |||||
2020-04-02 | MYOK | Myokardia, Inc. | Gianakakos Anastasios | Pres, CEO | S - Sale | $44.77 | -2,500 | 665,369 | 0% | -$111,917 | ||||||
2020-04-02 | MRUS | Merus N.V. | Throsby Mark | EVP, Chief Scientific Officer | S - Sale | $10.93 | -368 | 44,495 | -1% | -$4,022 | ||||||
2020-04-03 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $143.19 | -26,723 | 113,078,581 | 0% | -$3,826,493 | ||||||
2020-04-03 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.15 | +50,000 | 221,517,822 | 0% | +$57,592 | ||||||
2020-04-01 | STML | Stemline Therapeutics Inc | Gionco David | Chief Accounting Officer | S - Sale | $4.79 | -11,524 | 282,878 | -4% | -$55,200 | ||||||
2020-04-01 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | COB, CEO | S - Sale | $9.08 | -9,755 | 1,014,591 | -1% | -$88,608 | ||||||
| D | 2020-04-01 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | COO | S - Sale+OE | $9.09 | -15,003 | 362,858 | -4% | -$136,310 | |||||
| D | 2020-04-01 | FTSV | Forty Seven, Inc. | Takimoto Chris H | Chief Medical Officer | S - Sale+OE | $95.42 | -79,195 | 3,906 | -95% | -$7,556,787 | |||||
| D | 2020-04-01 | FTSV | Forty Seven, Inc. | Rhoads Ann D | CFO | S - Sale+OE | $95.42 | -1,924 | 37,414 | -5% | -$183,598 | |||||
| D | 2020-04-01 | FTSV | Forty Seven, Inc. | McCamish Mark Anthony | Pres, CEO | S - Sale+OE | $95.42 | -32,577 | 4,595 | -88% | -$3,108,504 | |||||
| D | 2020-04-01 | KRTX | Karuna Therapeutics, Inc. | Miller Andrew Craig | COO | S - Sale+OE | $64.37 | -25,000 | 0 | -100% | -$1,609,250 | |||||
| D | 2020-04-01 | KRTX | Karuna Therapeutics, Inc. | Brannan Stephen K. | Chief Medical Officer | S - Sale+OE | $67.36 | -7,728 | 7,500 | -51% | -$520,558 | |||||
| DM | 2020-04-02 | REGN | Regeneron Pharmaceuticals, Inc. | Landry Robert E | EVP Finance CFO | S - Sale+OE | $494.49 | -788 | 24,545 | -3% | -$389,659 | |||||
| M | 2020-04-01 | REGN | Regeneron Pharmaceuticals, Inc. | Landry Robert E | EVP Finance CFO | S - Sale | $488.90 | -1,848 | 25,161 | -7% | -$903,483 | |||||
2020-04-02 | PBYI | Puma Biotechnology, Inc. | Bryce Richard Paul | SEE REMARKS | S - Sale | $7.37 | -91 | 77,921 | 0% | -$671 | ||||||
2020-04-02 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $7.38 | -347 | 4,307,534 | 0% | -$2,563 | ||||||
2020-04-01 | PHAT | Phathom Pharmaceuticals, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.86 | +117,600 | 3,825,008 | +3% | +$2,923,642 | ||||||
| D | 2020-04-02 | ALKS | Alkermes Plc. | Pops Richard F | Dir, CEO, Alkermes plc | S - Sale+OE | $13.79 | -50,000 | 759,094 | -6% | -$689,500 | |||||
2020-04-01 | BBIO | Bridgebio Pharma, Inc. | Henderson Michael Thomas | See Remarks | S - Sale | $26.94 | -2,585 | 167,727 | -2% | -$69,629 | ||||||
| D | 2020-04-01 | STSA | Satsuma Pharmaceuticals, Inc. | Albrecht Detlef | Chief Medical Officer | S - Sale+OE | $20.25 | -200 | 20,012 | -1% | -$4,049 | |||||
2020-04-01 | BBIO | Bridgebio Pharma, Inc. | Stephenson Brian C | See Remarks | S - Sale | $26.61 | -7,200 | 330,316 | -2% | -$191,610 | ||||||
| M | 2020-04-01 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO, Pres | S - Sale | $26.02 | -77,895 | 8,180,888 | -1% | -$2,026,466 | |||||
| D | 2020-04-01 | DCPH | Deciphera Pharmaceuticals, Inc. | Taylor Michael Douglas | Dir | S - Sale+OE | $37.57 | -75,000 | 0 | -100% | -$2,817,558 | |||||
| D | 2020-04-02 | REGN | Regeneron Pharmaceuticals, Inc. | Larosa Joseph J | EVP GC, Secret | S - Sale+OE | $489.98 | -6,797 | 14,693 | -32% | -$3,330,406 | |||||
| D | 2020-04-01 | REGN | Regeneron Pharmaceuticals, Inc. | Fenimore Christopher R. | VP Controller | S - Sale+OE | $488.41 | -1,200 | 19,188 | -6% | -$586,096 | |||||
| M | 2020-04-01 | MYOV | Myovant Sciences Ltd. | Sumitomo Chemical Co., Ltd. | 10% | P - Purchase | $7.60 | +140,000 | 46,928,604 | 0% | +$1,063,384 | |||||
| M | 2020-04-01 | EMMA | Emmaus Life Sciences, Inc. | Niihara Yutaka | COB, CEO, 10% | P - Purchase | $1.26 | +30,800 | 10,717,837 | 0% | +$38,784 | |||||
2020-04-02 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $140.78 | -166,038 | 113,105,304 | 0% | -$23,374,654 | ||||||
2020-04-02 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.16 | +500,000 | 221,467,822 | 0% | +$581,185 | ||||||
2020-03-31 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.25 | +200 | 7,215,456 | 0% | +$50 | ||||||
2020-03-31 | EMMA | Emmaus Life Sciences, Inc. | Niihara Yutaka | COB, CEO, 10% | P - Purchase | $1.21 | +13,200 | 10,687,037 | 0% | +$15,972 | ||||||
2020-04-01 | BMRN | Biomarin Pharmaceutical Inc | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | S - Sale | $82.00 | -1,537 | 65,471 | -2% | -$126,034 | ||||||
| M | 2020-03-31 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $2.28 | -6,561 | 692,672 | -1% | -$14,952 | |||||
| M | 2020-03-31 | SPPI | Spectrum Pharmaceuticals Inc | Riga Thomas J | EVP, COO, CCO | S - Sale | $2.28 | -2,792 | 433,783 | -1% | -$6,373 | |||||
| D | 2020-04-01 | BCEL | Atreca, Inc. | Greenberg Norman Michael | Chief Scientific Officer | S - Sale+OE | $15.21 | -2,000 | 0 | -100% | -$30,422 | |||||
| M | 2020-03-31 | SPPI | Spectrum Pharmaceuticals Inc | McGahan Keith M | GC | S - Sale | $2.27 | -3,253 | 292,218 | -1% | -$7,395 | |||||
| M | 2020-03-31 | SPPI | Spectrum Pharmaceuticals Inc | Gustafson Kurt A | EVP, CFO | S - Sale | $2.28 | -7,461 | 372,670 | -2% | -$16,980 | |||||
| M | 2020-03-31 | NGM | Ngm Biopharmaceuticals Inc | Svennilson Peter | Dir, 10% | P - Purchase | $12.40 | +250,984 | 17,476,061 | +1% | +$3,111,021 | |||||
| M | 2020-03-31 | NGM | Ngm Biopharmaceuticals Inc | Goeddel David V | Dir, 10% | P - Purchase | $12.40 | +250,984 | 17,646,061 | +1% | +$3,111,021 | |||||
| M | 2020-03-31 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | 10% | P - Purchase | $12.40 | +250,984 | 17,471,061 | +1% | +$3,111,021 | |||||
| M | 2020-03-31 | NGM | Ngm Biopharmaceuticals Inc | Column Group L P | 10% | P - Purchase | $12.40 | +250,984 | 17,471,061 | +1% | +$3,111,021 | |||||
2020-04-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $14.36 | -500 | 72,142 | -1% | -$7,181 | ||||||
| D | 2020-04-02 | IMGN | Immunogen, Inc. | Foster David G | VP-Fin., Prin. Acctg. Officer | S - Sale+OE | $3.43 | -5,448 | 21,382 | -20% | -$18,687 | |||||
| DM | 2019-05-31 | SNSS | Sunesis Pharmaceuticals Inc | Quinn William P. | See Remarks | P - Purchase | $0.51 | +12,000 | 127,697 | +10% | +$6,070 | |||||
2020-04-01 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.23 | +643,549 | 220,967,822 | 0% | +$793,012 | ||||||
| M | 2020-03-30 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $475.27 | -200 | 28,943 | -1% | -$95,054 | |||||
| M | 2020-03-30 | ATHX | Athersys, Inc / New | Campbell Laura K | Senior Vice Pres Finance | S - Sale | $3.34 | -234,306 | 371,628 | -39% | -$782,586 | |||||
| M | 2020-03-31 | RYTM | Rhythm Pharmaceuticals, Inc. | Foley Todd | Dir | S - Sale | $15.13 | -34,570 | 2,324,893 | -1% | -$523,153 | |||||
| M | 2020-03-30 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | Vice COB, COO | P - Purchase | $1.26 | +4,500 | 324,385 | +1% | +$5,665 | |||||
2020-03-31 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $140.07 | -38,962 | 113,271,342 | 0% | -$5,457,474 | ||||||
2020-03-30 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.05 | -20,000 | 23,958,546 | 0% | -$20,906 | ||||||
| M | 2020-03-30 | MYOV | Myovant Sciences Ltd. | Sumitomo Chemical Co., Ltd. | 10% | P - Purchase | $7.81 | +140,000 | 46,788,604 | 0% | +$1,093,750 | |||||
| AM | 2020-03-13 | ENZN | Enzon Pharmaceuticals, Inc. | Couchman Jonathan | 10% | P - Purchase | $0.14 | +652,723 | 7,345,162 | +10% | +$91,283 | |||||
| M | 2020-03-27 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $2.37 | +111,914 | 29,400,961 | 0% | +$265,346 | |||||
| M | 2020-03-27 | PHAT | Phathom Pharmaceuticals, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.58 | +60,600 | 3,707,408 | +2% | +$1,489,264 | |||||
| D | 2020-03-30 | HZNP | Horizon Therapeutics Public Ltd Co | Moze Barry | EVP, Chief Admin. Officer | S - Sale+OE | $28.18 | -2,106 | 166,291 | -1% | -$59,347 | |||||
| D | 2020-03-27 | ARMP | Armata Pharmaceuticals, Inc. | Innoviva, Inc. | 10% | P - Purchase | $2.87 | +7,717,661 | 8,710,800 | +777% | +$22,149,687 | |||||
| D | 2019-07-23 | RZLT | Rezolute, Inc. | Handok, Inc. | 10% | P - Purchase | $0.29 | +34,482,758 | 91,300,933 | +61% | +$10,000,000 | |||||
| D | 2020-03-30 | ASMB | Assembly Biosciences, Inc. | Papkoff Jacqueline Sybil | SVP-CSO Microbiome | S - Sale+OE | $14.22 | -1,254 | 38,661 | -3% | -$17,831 | |||||
| D | 2020-03-31 | ASMB | Assembly Biosciences, Inc. | Colonno Richard James | EVP, CSO, Virology Ops | S - Sale+OE | $15.04 | -7,812 | 137,009 | -5% | -$117,524 | |||||
2020-03-30 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $139.11 | -210,000 | 113,310,304 | 0% | -$29,213,559 | ||||||
2020-03-30 | LLY | Eli Lilly & Co | Fry Stephen F | SVP, HR, Diversity | S - Sale | $134.30 | -14,657 | 107,591 | -12% | -$1,968,434 | ||||||
2020-03-30 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.35 | +161,968 | 220,324,273 | 0% | +$218,037 | ||||||
| M | 2020-03-26 | EMMA | Emmaus Life Sciences, Inc. | Niihara Yutaka | COB, CEO, 10% | P - Purchase | $1.11 | +19,200 | 10,673,837 | 0% | +$21,364 | |||||
| M | 2020-03-13 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.25 | +300 | 7,215,256 | 0% | +$74 | |||||
| DM | 2020-03-27 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $4.11 | +9,000 | 8,691,122 | 0% | +$37,020 | |||||
2020-03-26 | RYTM | Rhythm Pharmaceuticals, Inc. | Foley Todd | Dir | S - Sale | $15.04 | -2,300 | 2,359,463 | 0% | -$34,592 | ||||||
| D | 2020-03-26 | EIDX | Eidos Therapeutics, Inc. | Valle Franco | SVP, Finance | S - Sale+OE | $48.26 | -5,000 | 0 | -100% | -$241,310 | |||||
| M | 2020-03-26 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | Vice COB, COO | P - Purchase | $1.14 | +6,800 | 319,885 | +2% | +$7,770 | |||||
| M | 2020-03-26 | MYOV | Myovant Sciences Ltd. | Sumitomo Chemical Co., Ltd. | 10% | P - Purchase | $7.96 | +140,000 | 46,648,604 | 0% | +$1,114,057 | |||||
2020-03-27 | ADIL | Adial Pharmaceuticals, Inc. | Newman James W. Jr. | Dir | P - Purchase | $1.36 | +19,644 | 269,732 | +8% | +$26,769 | ||||||
2020-03-27 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.40 | +100,000 | 220,162,305 | 0% | +$139,976 | ||||||
2020-03-26 | PRPH | Prophase Labs, Inc. | Gleckel Louis Md | Dir | P - Purchase | $1.75 | +100,000 | 209,894 | +91% | +$175,000 | ||||||
2020-03-26 | PRPH | Prophase Labs, Inc. | Karkus Ted William | CEO, COB, 10% | S - Sale | $1.75 | -100,000 | 2,549,528 | -4% | -$175,000 | ||||||
2020-03-25 | IONS | Ionis Pharmaceuticals Inc | Crooke Stanley T | Exec COB | S - Sale | $47.00 | -16,000 | 747,907 | -2% | -$752,000 | ||||||
| A | 2020-03-17 | IONS | Ionis Pharmaceuticals Inc | Crooke Stanley T | Exec COB | S - Sale | $44.75 | -20,000 | 772,326 | -3% | -$895,000 | |||||
2020-03-26 | TPTX | Turning Point Therapeutics, Inc. | Cui Jingrong Jean | Dir | S - Sale | $46.03 | -11,500 | 2,083,389 | -1% | -$529,372 | ||||||
2020-03-26 | MATN | Mateon Therapeutics Inc | Trieu Vuong | CEO | P - Purchase | $0.12 | +3,000 | 19,893,535 | 0% | +$360 | ||||||
| D | 2020-03-26 | UTHR | United Therapeutics Corp | Giltner Richard | Dir | S - Sale+OE | $91.75 | -5,000 | 3,750 | -57% | -$458,750 | |||||
| D | 2020-03-27 | ATNX | Athenex, Inc. | Lau Johnson Yiu Nam | CEO, COB, 10% | P - Purchase | $7.88 | +1,000 | 4,063,945 | 0% | +$7,880 | |||||
| D | 2020-03-27 | ATNX | Athenex, Inc. | Sze Randoll | CFO | P - Purchase | $8.19 | +1,000 | 5,000 | +25% | +$8,190 | |||||
2020-03-26 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.38 | +200,000 | 220,062,305 | 0% | +$275,445 | ||||||
| M | 2020-03-25 | ADIL | Adial Pharmaceuticals, Inc. | Stilley William B. III | CEO, 10% | P - Purchase | $1.30 | +25,000 | 715,937 | +4% | +$32,552 | |||||
2020-03-25 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controller | S - Sale | $15.28 | -212 | 4,961 | -4% | -$3,239 | ||||||
2020-03-25 | EPZM | Epizyme, Inc. | Tombesi Paolo | CFO | S - Sale | $15.28 | -1,243 | 15,437 | -7% | -$18,993 | ||||||
2020-03-25 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | S - Sale | $15.28 | -1,243 | 51,798 | -2% | -$18,993 | ||||||
| D | 2020-03-25 | EPZM | Epizyme, Inc. | Bazemore Robert B | Pres, CEO | S - Sale+OE | $15.28 | -3,285 | 254,371 | -1% | -$50,195 | |||||
2020-03-25 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Officer | S - Sale | $15.28 | -1,243 | 71,991 | -2% | -$18,993 | ||||||
| M | 2020-03-24 | BMRN | Biomarin Pharmaceutical Inc | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | S - Sale | $76.18 | -3,659 | 67,008 | -5% | -$278,733 | |||||
| D | 2020-03-24 | EYEN | Eyenovia, Inc. | Ianchulev Tsontcho | CEO, 10% | P - Purchase | $2.27 | +82,431 | 1,574,679 | +6% | +$187,118 | |||||
| D | 2020-03-24 | EYEN | Eyenovia, Inc. | Mario Ernest | Dir | P - Purchase | $2.27 | +82,431 | 327,239 | +34% | +$187,118 | |||||
| DM | 2020-03-24 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $4.41 | +3,000 | 8,682,122 | 0% | +$13,240 | |||||
| D | 2020-03-25 | ATNX | Athenex, Inc. | Fok Manson | Dir | P - Purchase | $7.25 | +50,000 | 2,755,670 | +2% | +$362,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |